SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Immunomedics (IMMU) - moderated

20 Oct 2022 10:42 PM
18 Dec 2020 06:56 PM
02 Sep 2020 07:03 PM
28 Aug 2020 10:59 PM
19 Aug 2020 02:21 PM
17 Jul 2020 01:47 PM
29 Jun 2020 11:30 AM
06 May 2020 09:45 PM
06 May 2020 02:45 PM
06 May 2020 01:08 PM <--
28 Nov 2018 06:58 PM
27 Nov 2018 10:59 PM
16 Aug 2018 01:37 PM
02 Aug 2018 02:20 PM
02 Aug 2018 12:37 PM
18 Jul 2018 10:49 AM
23 May 2018 11:21 PM
15 Dec 2016 12:56 PM
24 Aug 2014 10:16 AM
13 Jun 2013 08:03 AM
05 Jul 2011 10:42 AM
13 Oct 2010 10:05 AM
10 Oct 2010 10:39 AM
08 Mar 2010 08:32 AM
25 Nov 2009 03:28 PM
27 Oct 2009 09:05 PM
25 Oct 2009 06:57 PM
29 May 2009 02:59 PM
01 Mar 2009 10:32 AM
28 Nov 2007 08:09 PM
09 Apr 2007 08:32 PM
15 Feb 2007 09:40 PM
07 Jan 2007 10:29 AM
12 Dec 2006 08:08 AM
08 Nov 2006 09:32 PM
08 Oct 2006 07:47 PM
05 Oct 2006 07:43 AM
09 Sep 2006 08:57 PM

Return to Immunomedics (IMMU) - moderated
 
Welcome to the troll-free, moderated message board for Immunomedics (IMMU).

IMMU is in a very exciting phase, one that promises real benefits for patients.

As far as the company is concerned:
- the new management (aka Gold for the proxy ballot color) is delivering on the stated plan
- 132, now known as Trodelvy, has received AA (accelerated approval).
- The phase lll Ascent trial has been halted for “compelling efficacy” pretty much assuring full and final approval later this year, 2020.
- the share price has enjoyed a very nice run-up since January 2017
- Cash in the bank is at an all time high after an over subscribed offering was completed in April 2020 and raised $420 million.
- IMMU sold it’s first treatment of Trodelvy April 29th, 2020.

- IMMU's status:
-- Company website:
-- immunomedics.com

Clinical trials

Prostate cancer
clinicaltrials.gov

Trodelvy combined with PARP for TNBC
clinicaltrials.gov

Phase lll Ascent trial. Halted for compelling efficacy
clinicaltrials.gov

Rollover Study for patients who are still responding after their trial has ended
clinicaltrials.gov

Study of IMMU-132 in HR+/HER2- MBC (TROPICs-02)https://clinicaltrials.gov/ct2/show/NCT03901339?term=Immu-132&cond=Cancer&draw=2&rank=6
Trodelvy in TNBC (NeoSTAR). Primary end point—% of complete responses in treatment naive patients.
clinicaltrials.gov

A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03)
clinicaltrials.gov
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
clinicaltrials.gov

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)
clinicaltrials.gov

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
clinicaltrials.gov

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
clinicaltrials.gov

Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
clinicaltrials.gov

Now that we have approval of a potential blockbuster treatment in Trodelvy, where do we go from here?
I’ll be listing some posts that suggest where things go from here.

Etiquette:

This board is moderated, meaning the moderator (me) can stop people from posting here if they violate our norms. What are "our norms"? Well, be adult, play nice about sums it up. There are three responses I encourage for keeping the discussion civil and useful when you encounter a post that annoys you. In order of preference:

1> report a ToU violation to the SI admins via the link at the bottom of each post, they're good at dealing with problems.

2> send the person who posted a private message and work it out. Privately.

3> send me a private message. Wait a couple of days before doing so please, I'll usually see the message in that time frame and act (or not).

4> stay focused on IMMU and leave politics out of it, even by inference. There are numerous forums you can spend as much time expounding on your favorite "why (insert favorite hot-button) is evil", we don't need to reiterate all that here.

5> do not engage in discussions about poster's motivations, etc. First of all, it's unprovable. Second I'd rather not wade through the inevitable pointless back-and-forth over something that'll never be settled anyway.

This board provides a forum for honest, civilized and friendly conversation. It is not a vehicle for spam or hidden agendas. New posters are not only welcome but are an important way to bring additional information and insights to the board. Over the years new posters have been welcomed into the group and have helped make the board successful. However, if you’re a new poster it is especially important to be sure that material assertions, be they pro or con, are thoughtful and supportable. While all posters must abide by the TOU, leeway can and will be granted to long-time posters who have made substantive contributions to the board and whose credibility has been established.

Please consider becoming a paid member. The SI admins do a very good job at keeping this board useful/fun. If you derive value from this forum, then SI deserves your support!

Finally, we all have internet connections and the like, please just skip all the breathless "It's up/down $X.Y in the first hour!" posts. Short-term price moves are generally noise anyway absent major news so we can wait until the evening to discuss price moves if we discuss them at all.

Again, welcome! I think you'll find this a place to learn about and contribute to others' understanding of IMMU and its prospects.